Briacell Therapeutics Debt
BCTX Stock | USD 0.60 0.02 3.97% |
Total Debt To Capitalization is likely to rise to 0.0005 in 2024, whereas Net Debt is likely to drop (905.2 K) in 2024. With a high degree of financial leverage come high-interest payments, which usually reduce Briacell Therapeutics' Earnings Per Share (EPS).
Debt Ratio | First Reported 2010-12-31 | Previous Quarter 0.000515 | Current Value 0.000489 | Quarterly Volatility 0.25704723 |
Given that Briacell Therapeutics' debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Briacell Therapeutics is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Briacell Therapeutics to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Briacell Therapeutics is said to be less leveraged. If creditors hold a majority of Briacell Therapeutics' assets, the Company is said to be highly leveraged.
At this time, Briacell Therapeutics' Total Current Liabilities is fairly stable compared to the past year. Liabilities And Stockholders Equity is likely to rise to about 10.3 M in 2024, whereas Non Current Liabilities Total is likely to drop slightly above 1 M in 2024. Briacell |
Briacell Therapeutics Bond Ratings
Briacell Therapeutics Corp financial ratings play a critical role in determining how much Briacell Therapeutics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Briacell Therapeutics' borrowing costs.Piotroski F Score | 2 | Frail | View |
Beneish M Score | (8.79) | Unlikely Manipulator | View |
Briacell Therapeutics Debt to Cash Allocation
As Briacell Therapeutics Corp follows its natural business cycle, the capital allocation decisions will not magically go away. Briacell Therapeutics' decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors.
Briacell Therapeutics Corp currently holds 8.56 M in liabilities. Briacell Therapeutics has a current ratio of 44.1, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Briacell Therapeutics' use of debt, we should always consider it together with its cash and equity.Briacell Therapeutics Total Assets Over Time
Briacell Therapeutics Assets Financed by Debt
The debt-to-assets ratio shows the degree to which Briacell Therapeutics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.Briacell Therapeutics Debt Ratio | 0.0489 |
Briacell Therapeutics Corporate Bonds Issued
Briacell Net Debt
Net Debt |
|
Understaning Briacell Therapeutics Use of Financial Leverage
Understanding the structure of Briacell Therapeutics' debt obligations provides insight if it is worth investing in it. Financial leverage can amplify the potential profits to Briacell Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its cost of debt.
Last Reported | Projected for Next Year | ||
Net Debt | -862.1 K | -905.2 K | |
Short and Long Term Debt Total | 23.4 K | 22.2 K | |
Short and Long Term Debt | 276.2 K | 262.4 K | |
Short Term Debt | 205.9 K | 195.6 K | |
Long Term Debt | 23.4 K | 22.2 K | |
Net Debt To EBITDA | 0.90 | 0.85 | |
Cash Flow To Debt Ratio | (342.87) | (325.73) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Briacell Stock Analysis
When running Briacell Therapeutics' price analysis, check to measure Briacell Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Briacell Therapeutics is operating at the current time. Most of Briacell Therapeutics' value examination focuses on studying past and present price action to predict the probability of Briacell Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Briacell Therapeutics' price. Additionally, you may evaluate how the addition of Briacell Therapeutics to your portfolios can decrease your overall portfolio volatility.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.